Pain Research and Treatment / 2012 / Article / Tab 11

Clinical Study

Validation of the Self-Assessment of Treatment Questionnaire among Patients with Postherpetic Neuralgia

Table 11

Concurrent validity: ANOVA models of BPI change scores by SAT scores at Week 12 (pooled dataset; )1.

SATBPI change scores at Week 12
Pain at its worst in last 24 hoursPain at its least in the last 24 hours
NLS mean (SE) -valueNLS mean (SE) -value

(1) How do you assess your pain level after treatment in this study?Better340−3.6 (0.1)<0.0001340−1.3 (0.1)<0.0001
No change309−0.8 (0.1)3090.7 (0.1)
Worse470.5 (0.3)471.3 (0.3)
(2) How do you assess your activity level after treatment in this study?Better210−4.1 (0.2)<0.0001210−1.5 (0.1)<0.0001
No change451−1.3 (0.1)4510.3 (0.1)
Worse350.2 (0.4)35(0.4)
(3) How has your quality of life changed after treatment in this study?Better266−3.8 (0.1)<0.0001266−1.4 (0.1)<0.0001
No change408−1.1 (0.1)4080.5 (0.1)
Worse220.3 (0.5)22(0.4)
(4) Would you undergo this treatment again?Better450−2.6 (0.1)<0.0001450−0.6 (0.1)<0.0001
No change173−1.1 (0.2)1730.5 (0.2)
Worse73−0.9 (0.3)73(0.3)
(5) How do you compare the treatment you received in this study to previous medication or therapies for your pain?Better295−3.3 (0.1)<0.0001295−1.1 (0.1)<0.0001
No change312−1.3 (0.1)3120.4 (0.1)
Worse89−1.0 (0.3)890.3 (0.2)
SAT treatment effect subscale (Items 1, 2, and 3)Better358−3.5 (0.1)<0.0001358−1.2 (0.1)<0.0001
No change279−0.8 (0.1)2790.7 (0.1)
Worse590.4 (0.3)591.2 (0.3)
SAT treatment satisfaction subscale (Items 4 and 5)Better447−2.7 (0.1)<0.0001447−0.6 (0.1)<0.0001
No change141−1.0 (0.2)1410.6 (0.2)
Worse108−0.9 (0.3)1080.5 (0.2)

ANOVA: analysis of variance; BPI: Brief Pain Inventory; LS: least-squares; SAT: Self-Assessment of Treatment; SE: standard error.
oncurrent validity was evaluated using ANOVA to compare BPI changes in pain by SAT response levels (patients improved; no change; worsened). Pooled dataset included data from two clinical trials, Studies C116 ( ) and C117 ( ).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.